ArriVent BioPharma, Inc. (AVBP) Balance Sheet
AVBP balance sheet, FY2025
September 30, 2025 · U.S. dollars$333.2M assets = $25.9M liabilities + $307.2M equity
Both columns are drawn to the same scale: what AVBP owns equals what it owes plus shareholders’ equity. Hover a block for its value.
AVBP financial health
Descriptive bands, not a rating. Fiscal FY2025.
AVBP balance sheet trends, FY2021–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $43.0MFY2021 | $333.2MFY2025 | +66.8%/yr | |
| Total liabilities | $1.8MFY2021 | $25.9MFY2025 | +94.4%/yr | |
| Shareholders’ equity | $41.2MFY2021 | $307.2MFY2025 | +65.2%/yr | |
| Cash & short-term investments | $37.3MFY2021 | $312.8MFY2025 | +70.2%/yr | |
| Total debt | $139,000FY2022 | $14,000FY2025 | −53.5%/yr | |
| Net cash (debt) | $163.2MFY2022 | $312.8MFY2025 | +$149.6M | |
| Working capital | $41.1MFY2021 | $307.0MFY2025 | +$265.8M | |
| Book value per share | $5.21FY2022 | $7.99FY2025 | +15.3%/yr | |
| Debt / equity | 0.00FY2022 | 0.00FY2025 | 0.00 | |
| Shares outstanding | 33.5MFY2022 | 38.5MFY2025 | +4.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AVBP assets
AVBP liabilities and equity
AVBP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
AVBP balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $312.8M | $218.9M | $150.4M | $163.4M | $37.3M |
| Cash & equivalents | $45.5M | $74.3M | $150.4M | $163.4M | $37.3M |
| Short-term investments | $267.3M | $144.6M | $0 | — | — |
| Receivables | $60,000 | $500,000 | $761,000 | $500,000 | $250,000 |
| Inventory | $0 | $0 | −$240,000 | $0 | $0 |
| Other current assets | $20.0M | $7.6M | $9.1M | $18.8M | $5.4M |
| Total current assets | $332.9M | $227.0M | $160.0M | $182.6M | $43.0M |
| Property, plant & equipment (net) | $13,000 | $154,000 | $291,000 | $139,000 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $47.7M | $0 | $0 | $0 |
| Other non-current assets | $259,000 | $126,000 | $2.8M | $72,000 | $87,000 |
| Total assets | $333.2M | $274.9M | $163.1M | $182.8M | $43.0M |
| Liabilities | |||||
| Accounts payable | $5.9M | $3.8M | $4.5M | $3.1M | $293,000 |
| Short-term debt | $14,000 | $162,000 | $140,000 | $128,000 | — |
| Deferred revenue | — | — | — | −$1 | — |
| Total current liabilities | $25.9M | $17.3M | $11.6M | $8.4M | $1.8M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $14,000 | $176,000 | $317,000 | $139,000 | $0 |
| Other long-term liabilities | $0 | $14,000 | $177,000 | $11,000 | $0 |
| Total liabilities | $25.9M | $17.3M | $11.8M | $8.4M | $1.8M |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $4,000 | $3,000 | — | $4,000 | $4,000 |
| Retained earnings (deficit) | −$404.6M | −$238.3M | −$157.8M | −$88.5M | −$51.6M |
| Accumulated other comprehensive income | $14,000 | −$211,000 | — | −$4,000 | −$2,000 |
| Total shareholders' equity | $307.2M | $257.7M | $151.3M | $174.5M | $41.2M |
| Key figures | |||||
| Total debt | $14,000 | $176,000 | $317,000 | $139,000 | — |
| Net cash (debt) | $312.8M | $218.7M | $150.1M | $163.2M | — |
| Working capital | $307.0M | $209.7M | $148.3M | $174.3M | $41.1M |
| Tangible book value | $307.2M | $257.7M | $151.3M | $174.5M | $41.2M |
| Book value per share | $7.99 | $8.19 | $4.73 | $5.21 | — |
| Shares outstanding | 38.5M | 31.5M | 32.0M | 33.5M | — |
| Current ratio | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
| Quick ratio | 12.06 | 12.70 | 13.00 | 19.60 | 20.64 |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Equity / assets | 92.2% | 93.7% | 92.8% | 95.4% | 95.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $373.1M | $326.4M | $312.8M | $300.3M | $235.7M | $176.1M | $218.9M | $282.9M | $298.7M | $317.4M | $150.4M | $166.4M |
| Cash & equivalents | $154.7M | $62.1M | $45.5M | $112.7M | $112.8M | $49.9M | $74.3M | $282.9M | $298.7M | $317.4M | $150.4M | $141.4M |
| Short-term investments | $218.4M | $264.3M | $267.3M | $187.6M | $122.9M | $126.2M | $144.6M | — | — | — | — | $25.0M |
| Receivables | $0 | $0 | $60,000 | $505,000 | $505,000 | $505,000 | $500,000 | $500,000 | $750,000 | $875,000 | $761,000 | $1.1M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $21.1M | $22.3M | $20.0M | $20.4M | $14.0M | $9.2M | $7.6M | $9.0M | $9.1M | $9.2M | $8.8M | $12.5M |
| Total current assets | $394.2M | $348.7M | $332.9M | $321.2M | $250.1M | $185.8M | $227.0M | $292.4M | $308.5M | $327.5M | $160.0M | $180.0M |
| Property, plant & equipment (net) | $370,000 | $370,000 | $13,000 | $49,000 | $85,000 | $120,000 | $154,000 | $187,000 | $219,000 | $250,000 | $291,000 | $44,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $5.1M | $18.8M | $29.4M | $47.7M | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $175,000 | $225,000 | $259,000 | $180,000 | $479,000 | $176,000 | $126,000 | $126,000 | $125,000 | $108,000 | $2.8M | $2.0M |
| Total assets | $394.7M | $349.3M | $333.2M | $326.6M | $269.5M | $215.5M | $274.9M | $292.7M | $308.9M | $327.8M | $163.1M | $182.0M |
| Liabilities | ||||||||||||
| Accounts payable | $2.2M | $8.7M | $5.9M | $5.9M | $4.1M | $4.4M | $3.8M | $4.6M | $3.8M | $4.1M | $4.5M | $4.8M |
| Short-term debt | $318,000 | $99,000 | $14,000 | $56,000 | $98,000 | $138,000 | $162,000 | $297,000 | $152,000 | $147,000 | $140,000 | $44,000 |
| Total current liabilities | $27.8M | $25.0M | $25.9M | $21.6M | $19.6M | $13.0M | $17.3M | $15.2M | $12.1M | $10.0M | $11.6M | $10.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $351,000 | $419,000 | $14,000 | $56,000 | $98,000 | $138,000 | $176,000 | $317,000 | $250,000 | $285,000 | $317,000 | $44,000 |
| Other long-term liabilities | $33,000 | $320,000 | $0 | $0 | $0 | $0 | $14,000 | $56,000 | $98,000 | $138,000 | $177,000 | $304.5M |
| Total liabilities | $27.9M | $25.3M | $25.9M | $21.6M | $19.6M | $13.0M | $17.3M | $15.2M | $12.2M | $10.1M | $11.8M | $10.1M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $5,000 | $5,000 | $4,000 | $4,000 | $4,000 | $4,000 | $3,000 | $3,000 | $3,000 | $3,000 | — | $4,000 |
| Retained earnings (deficit) | −$497.9M | −$448.0M | −$404.6M | −$369.1M | −$334.1M | −$302.7M | −$238.3M | −$217.7M | −$197.1M | −$175.3M | −$157.8M | −$136.7M |
| Accumulated other comprehensive income | −$267,000 | −$270,000 | $14,000 | $206,000 | −$18,000 | −$17,000 | −$211,000 | — | $0 | — | — | −$106,000 |
| Total shareholders' equity | $366.8M | $324.0M | $307.2M | $305.0M | $249.9M | $202.5M | $257.7M | $277.5M | $296.7M | $317.7M | $151.3M | $171.9M |
| Key figures | ||||||||||||
| Total debt | $351,000 | $419,000 | $14,000 | $56,000 | $98,000 | $138,000 | $176,000 | $353,000 | $250,000 | $285,000 | $317,000 | $44,000 |
| Net cash (debt) | $372.8M | $326.0M | $312.8M | $300.2M | $235.6M | $175.9M | $218.7M | $282.5M | $298.4M | $317.1M | $150.1M | $166.3M |
| Working capital | $366.3M | $323.7M | $307.0M | $299.7M | $230.5M | $172.8M | $209.7M | $277.2M | $296.4M | $317.5M | $148.3M | $169.9M |
| Tangible book value | $366.8M | $324.0M | $307.2M | $305.0M | $249.9M | $202.5M | $257.7M | $277.5M | $296.7M | $317.7M | $151.3M | $171.9M |
| Book value per share | $7.71 | $7.19 | $7.99 | $7.28 | $7.14 | $5.97 | $7.67 | $8.26 | $8.85 | $9.49 | $4.52 | $5.13 |
| Shares outstanding | 47.6M | 45.1M | 38.5M | 41.9M | 35.0M | 33.9M | 33.6M | 33.6M | 33.5M | 33.5M | 33.5M | 33.5M |
| Current ratio | 14.16 | 13.95 | 12.83 | 14.90 | 12.74 | 14.34 | 13.14 | 19.28 | 25.50 | 32.82 | 13.76 | 17.82 |
| Quick ratio | 13.40 | 13.06 | 12.06 | 13.95 | 12.03 | 13.63 | 12.70 | 18.69 | 24.75 | 31.90 | 13.00 | 16.58 |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity / assets | 92.9% | 92.8% | 92.2% | 93.4% | 92.7% | 94.0% | 93.7% | 94.8% | 96.1% | 96.9% | 92.8% | 94.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 5, 2026); data from EODHD.
AVBP financial position
At the end of fiscal 2025 (September 30, 2025), ArriVent BioPharma had total assets of $333.2 million (up 21.2% from a year earlier), total liabilities of $25.9 million and shareholders' equity of $307.2 million. It held $312.8 million in cash and short-term investments against $0.0 million of debt, a net cash position of $312.8 million. Its current ratio was 12.83. In the latest quarter (ended June 30, 2026) total assets were $394.7 million and equity $366.8 million.
Related: AVBP income statement, AVBP cash flow statement, AVBP key metrics. See the AVBP stock overview for the latest quote and news.
AVBP balance sheet FAQ
What are ArriVent BioPharma's total assets?
ArriVent BioPharma reported total assets of $333.2 million at the end of fiscal 2025 (September 30, 2025), compared with $274.9 million a year earlier.
How much debt does ArriVent BioPharma have?
ArriVent BioPharma had $0.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.
How much cash does ArriVent BioPharma have?
ArriVent BioPharma held $312.8 million in cash and short-term investments at the end of fiscal 2025; with $0.0 million of debt that is net cash of $312.8 million.
What is ArriVent BioPharma's book value?
ArriVent BioPharma's shareholders' equity (book value) was $307.2 million at the end of fiscal 2025, or $7.99 per share.
What is ArriVent BioPharma's current ratio?
ArriVent BioPharma had current assets of $332.9 million and current liabilities of $25.9 million, a current ratio of 12.83 (it can cover its short-term obligations).